Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18043288 | 1.00 | CYP1A2 (0.33) | CYP1A2TDP1HPGDALOX15KDM4E | |
| SCHEMBL18043296 | 0.85 | PARP1 (0.35) | — | |
| SCHEMBL18043297 | 0.85 | PARP1 (0.35) | — | |
| SCHEMBL18043334 | 0.83 | PARP1 (0.36) | ALDH1A1 | |
| SCHEMBL18043335 | 0.83 | PARP1 (0.36) | ALDH1A1 | |
| SCHEMBL18043331 | 0.81 | SMN1; SMN2 (0.40) | TDP1KDM4EALDH1A1 | |
| SCHEMBL18043328 | 0.81 | SMN1; SMN2 (0.40) | TDP1KDM4EALDH1A1 | |
| SCHEMBL18043123 | 0.80 | HPGD (0.34) | HPGDKDM4E | |
| SCHEMBL18043142 | 0.80 | KDM4E (0.36) | HPGDKDM4EALDH1A1 | |
| SCHEMBL18043141 | 0.80 | KDM4E (0.36) | HPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2016-09-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | BMX, BLK, ITK | CYP1A2 3405/4885TDP1 1189/4885HPGD 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.